Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 14/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16697625 | 1.00 | ADRB2 (0.56) | ADRB2CHRM3ADRB1ADRB3DRD2 | |
| SCHEMBL16697629 | 1.00 | ADRB2 (0.56) | ADRB2CHRM3ADRB1ADRB3DRD2 | |
| SCHEMBL20357834 | 0.91 | ADRB2 (0.56) | ADRB2CHRM3ADRB1ADRB3DRD2 | |
| SCHEMBL20357836 | 0.91 | ADRB2 (0.56) | ADRB2CHRM3ADRB1ADRB3DRD2 | |
| SCHEMBL20357835 | 0.91 | ADRB2 (0.56) | ADRB2CHRM3ADRB1ADRB3DRD2 | |
| SCHEMBL15776984 | 0.90 | ADRB2 (0.64) | ADRB2CHRM3ADRB1 | |
| SCHEMBL15776977 | 0.90 | ADRB2 (0.64) | ADRB2CHRM3ADRB1 | |
| SCHEMBL17074627 | 0.90 | ADRB2 (0.64) | ADRB2CHRM3ADRB1 | |
| SCHEMBL17074626 | 0.90 | ADRB2 (0.64) | ADRB2CHRM3ADRB1 | |
| SCHEMBL15776982 | 0.90 | ADRB2 (0.64) | ADRB2CHRM3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345904-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | Chiesi Farmaceutici S.p.a. (IT) | 2018-07-11 | — | — | EP | disclosed |